	US 11,946,070 B2
	Method of reinforcing efficacy of stem cells using ethionamide
Duk Lyul Na, Seoul (KR); Jong Wook Chang, Seoul (KR); and Hyo Jin Son, Seoul (KR)
Assigned to SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, Seoul (KR)
Appl. No. 17/054,939
Filed by SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, Seoul (KR)
PCT Filed Jul. 15, 2020, PCT No. PCT/KR2020/009312 § 371(c)(1), (2) Date Nov. 12, 2020, PCT Pub. No. WO2021/010745, PCT Pub. Date Jan. 21, 2021.
Claims priority of application No. 10-2019-0085137 (KR), filed on Jul. 15, 2019; and application No. 10-2020-0086685 (KR), filed on Jul. 14, 2020.
Prior Publication US 2021/0261915 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0735 (2010.01); A61K 35/51 (2015.01); A61K 35/545 (2015.01); A61P 25/28 (2006.01); A61P 29/00 (2006.01); C12N 5/0775 (2010.01)

CPC C12N 5/0606 (2013.01) [A61K 35/51 (2013.01); A61K 35/545 (2013.01); A61P 25/28 (2018.01); A61P 29/00 (2018.01); C12N 5/0665 (2013.01); C12N 2501/999 (2013.01)]

3 Claims

1. A method of reinforcing the efficacy of mesenchymal stem cells, comprising:

culturing stem cells for 72 hours in a medium comprising 10-200 μM ethionamide,

wherein the efficacy reinforcement is an improvement in expression of a paracrine factor in the stem cells, and

wherein the paracrine factor is one or more selected from the group consisting of a brain-derived neurotrophic issue (BDNF), a vascular endothelial cell growth factor (VEGF), insulin-like growth factor-1 (IGF-1), a hepatocyte growth factor (HGF), heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase (NQO1), a glutamate-cysteine ligase catalytic subunit (GCLC) and a glutamate-cysteine ligase modifier subunit (GCLM).